Current Neuro-Oncology

Volume 24 Number 23
15 December 2022

Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 23, 15 December

Castro MP, Khanlou N, Fallah A, Pampana A, Alam A, Lala DA, Roy KGG, Amara ARR, Prakash A, Singh D, Behura L, Kumar A, Kapoor S.
Targeting chromosome 12q amplification in relapsed glioblastoma: the use of computational biological modeling to identify effective therapy-a case report.
Ann Transl Med. 2022 Dec;10(23):1289∟. doi: 10.21037/atm-2022-62∟. PMID: 36618786∟. Case report. ˍ

Beige A, Ghiringhelli F, Lecuelle J, Truntzer C, Truc G, Vincent J, Farah W, Borsotti F, Mazilu I, Ilie SM.
Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study.
Anticancer Res. 2022 Dec 1;42(12):5847-5858∟. doi: 10.21873/anticanres.16093∟. PMID: 36456149∟. Observational study˰ ˍ

Moreno V, Sepulveda JM, Reardon DA, Pérez-Núñez Á, González León P, Hanna B, Filvaroff E, Aronchik I, Chang H, Amoroso B, Zuraek M, Sanchez-Perez T, Mendez C, Stephens D, Nikolova Z, Vogelbaum MA.
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, "windowofopportunity" study.
Neuro Oncol. 2022 Dec 1:noac263∟. doi: 10.1093/neuonc/noac263∟. PMID: 36455228∟. Interventional study. ˍ

Park JH, Lee HS, Choi JW, Lim SD, Koh HK, Cho KR, Cho J, Koh YC, Yoon SY.
Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors.
Anticancer Res. 2022 Dec 1;42(12):6091-6098∟. doi: 10.21873/anticanres.16121∟. PMID: 36456153∟. Observational study˰ ˍ

Sugimoto S, Ishida T, Kawada K, Jobu K, Morisawa S, Tamura N, Takuma D, Yoshioka S, Miyamura M.
Central Nervous System Ischemia Associated with Bevacizumab: An Analysis of the Japanese Adverse Drug Event Report Database.
Biol Pharm Bull. 2022 Dec 1;45(12):1805-1811∟. doi: 10.1248/bpb.b22-00496∟. PMID: 36450533∟. Observational study. ˍ

Vargas López AJ, Fernández Carballal C, Valera Melé M, Rodríguez-Boto G.
Survival analysis in high-grade glioma: The role of salvage surgery.
Neurologia (Engl Ed). 2022 Dec 1:S2173-5808(22)00181-X∟. doi: 10.1016/j.nrleng.2020.04.032∟. PMID: 36464224∟. Observational study. ˍ

Wiltgen T, Fleischmann DF, Kaiser L, Holzgreve A, Corradini S, Landry G, Ingrisch M, Popp I, Grosu AL, Unterrainer M, Bartenstein P, Parodi K, Belka C, Albert N, Niyazi M, Riboldi M.
¹⁸F-FET PET radiomics-based survival prediction in glioblastoma patients receiving radio(chemo)therapy.
Radiat Oncol. 2022 Dec 2;17(1):198∟. doi: 10.1186/s13014-022-02164-6∟. PMID: 36461120∟. Observational study. ˍ

Capuozzo S, Gravina M, Gatta G, Marrone S, Sansone C.
A Multimodal Knowledge-Based Deep Learning Approach for MGMT Promoter Methylation Identification.
J Imaging. 2022 Dec 3;8(12):321∟. doi: 10.3390/jimaging8120321∟. PMID: 36547486∟. Laboratory investigation. ˍ

González V, Brell M, Fuster J, Moratinos L, Alegre D, López S, Ibáñez J.
Analyzing the role of reoperation in recurrent glioblastoma: a 15-year retrospective study in a single institution.
World J Surg Oncol. 2022 Dec 4;20(1):384∟. doi: 10.1186/s12957-022-02852-3∟. PMID: 36464682∟. Observational study. ˍ

Jessa S, Mohammadnia A, Harutyunyan AS, Hulswit M, Varadharajan S, Lakkis H, Kabir N, Bashardanesh Z, Hébert S, Faury D, Vladoiu MC, Worme S, Coutelier M, Krug B, Faria Andrade A, Pathania M, Bajic A, Weil AG, Ellezam B, Atkinson J, Dudley RWR, Farmer JP, Perreault S, Garcia BA, Larouche V, Blanchette M, Garzia L, Bhaduri A, Ligon KL, Bandopadhayay P, Taylor MD, Mack SC, Jabado N, Kleinman CL.
K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas.
Nat Genet. 2022 Dec 5;54(12):1865-1880∟. doi: 10.1038/s41588-022-01205-w∟. PMID: 36471070∟. Laboratory investigation˰ ˍ

Li XN.
Defining the cell of origin for diffuse midline gliomas.
Nat Genet. 2022 Dec 5;54(12):1770-1771∟. doi: 10.1038/s41588-022-01231-8∟. PMID: 36471069∟. Comment˰ ˍ
Refers to: Jessa S, et al., K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas.
Nat Genet. 2022 Dec 5;54(12):1865-1880∟. doi: 10.1038/s41588-022-01205-w∟. PMID: 36471070∟. Laboratory investigation˰ ˍ
Refers to: Liu I, et al., The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.
Nat Genet. 2022 Dec 5;54(12):1881-1894∟. doi: 10.1038/s41588-022-01236-3∟. PMID: 36471067∟. Laboratory investigation. ˍ

Liu I, Jiang L, Samuelsson ER, Marco Salas S, Beck A, Hack OA, Jeong D, Shaw ML, Englinger B, LaBelle J, Mire HM, Madlener S, Mayr L, Quezada MA, Trissal M, Panditharatna E, Ernst KJ, Vogelzang J, Gatesman TA, Halbert ME, Palova H, Pokorna P, Sterba J, Slaby O, Geyeregger R, Diaz A, Findlay IJ, Dun MD, Resnick A, Suvà ML, Jones DTW, Agnihotri S, Svedlund J, Koschmann C, Haberler C, Czech T, Slavc I, Cotter JA, Ligon KL, Alexandrescu S, Yung WKA, Arrillaga-Romany I, Gojo J, Monje M, Nilsson M, Filbin MG.
The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.
Nat Genet. 2022 Dec 5;54(12):1881-1894∟. doi: 10.1038/s41588-022-01236-3∟. PMID: 36471067∟. Laboratory investigation. ˍ

Liu S, Zhang Y, Kong Z, Jiang C, Wang Y, Zhao D, You H, Ma W, Feng F.
Feasibility of evaluating the histologic and genetic subtypes of WHO grade II-IV gliomas by diffusion-weighted imaging.
BMC Neurosci. 2022 Dec 5;23(1):72∟. doi: 10.1186/s12868-022-00750-8∟. PMID: 36471242∟. Observational study. ˍ

Pando A, Patel AM, Chaudhry H, Eloy JA, Goldstein I, Liu JK.
Palliative Care Effects on Survival in Glioblastoma: Who Receives Palliative Care?
World Neurosurg. 2022 Dec 5:S1878-8750(22)01695-3∟. doi: 10.1016/j.wneu.2022.11.143∟. PMID: 36481442∟. Observational study˰ ˍ

White K, Connor K, Meylan M, Bougoüin A, Salvucci M, Bielle F, O'Farrell AC, Sweeney K, Weng L, Bergers G, Dicker P, Ashley DM, Lipp ES, Low JT, Zhao J, Wen P, Prins R, Verreault M, Idbaih A, Biswas A, Prehn JHM, Lambrechts D, Arijs I, Lodi F, Dilcan G, Lamfers M, Leenstra S, Fabro F, Ntafoulis I, Kros JM, J Cryan, Brett F, Quissac E, Beausang A, MacNally S, O'Halloran P, Clerkin J, Bacon O, Kremer A, Tching Chi Yen R, Varn FS, Verhaak RGW, Sautès-Fridman C, Fridman WH, Byrne AT.
Identification, validation and biological characterization of novel Glioblastoma Tumour Microenvironment subtypes: Implications for precision immunotherapy.
Ann Oncol. 2022 Dec 6:S0923-7534(22)04743-3∟. doi: 10.1016/j.annonc.2022.11.008∟. PMID: 36494005∟. Laboratory investigation. ˍ

Degorre C, Sutton IC, Lehman SL, Shankavaram UT, Camphausen K, Tofilon PJ.
Glioblastoma cells have increased capacity to repair radiation-induced DNA damage after migration to the olfactory bulb.
Cancer Cell Int. 2022 Dec 8;22(1):389∟. doi: 10.1186/s12935-022-02819-0∟. PMID: 36482431∟. Laboratory investigation. ˍ

*

Zhao M, Ma H, Cheng P, Yang H, Zhao Y, Han Q.
Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report.
Medicine (Baltimore). 2022 Dec 9;101(49):e32156∟. doi: 10.1097/MD.0000000000032156∟. PMID: 36626518∟. Case report. ˍ

Baliga S, Adams JA, Bajaj BVM, Van Benthuysen L, Daartz J, Gallotto SL, Lewy JR, DeNunzio N, Weyman EA, Lawell MP, Palmer JD, Yeap BY, Ebb DH, Huang MS, Perry AF, MacDonald SM, Jones RM, Tarbell NJ, Yock TI.
Patterns of failure in pediatric medulloblastoma and implications for hippocampal sparing.
Cancer. 2022 Dec 11∟. doi: 10.1002/cncr.34574∟. PMID: 36504293∟. Observational study. ˍ

Noble Anbunesan S, Alfonso-Garcia A, Zhou X, Bec J, Lee HS, Jin LW, Bloch O, Marcu L.
Intraoperative detection of IDH-mutant glioma using fluorescence lifetime imaging.
J Biophotonics. 2022 Dec 12:e202200291∟. doi: 10.1002/jbio.202200291∟. PMID: 36510639∟. Observational study˰ ˍ

Tsuji O, Nagoshi N, Suzuki S, Takahashi Y, Nori S, Yagi M, Matsumoto M, Nakamura M, Watanabe K.
Clinical Features of Recurrent Spinal Cord Tumors.
Spine Surg Relat Res. 2022 Dec 12;7(3):225-234∟. doi: 10.22603/ssrr.2022-0136∟. PMID: 37309498∟. Observational study. ˍ

Yang J, Kwon JW, Shin SH, Yoo H, Wang KC, Lee SH, Gwak HS.
Leptomeningeal Metastasis in Gliomas: Clinical Characteristics and Risk Factors.
J Korean Neurosurg Soc. 2022 Dec 12∟. doi: 10.3340/jkns.2022.0166∟. PMID: 36503217∟. Observational study. ˍ

Li S, Li R, Li M, Cui Q, Zhang X, Ma T, Wang D, Zeng M, Li H, Bao Z, Peng Y, Sessler DI.
Dexmedetomidine administration during brain tumour resection for prevention of postoperative delirium: a randomised trial.
Br J Anaesth. 2022 Dec 13;130(2):e307-e316∟. doi: 10.1016/j.bja.2022.10.041∟. PMID: 36517290∟. Interventional study˰ ˍ

Bota DA, Taylor TH, Piccioni DE, Duma CM, LaRocca RV, Kesari S, Carrillo JA, Abedi M, Aiken RD, Hsu FPK, Kong XT, Hsieh C, Bota PG, Nistor GI, Keirstead HS, Dillman RO.
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
J Exp Clin Cancer Res. 2022 Dec 14;41(1):344∟. doi: 10.1186/s13046-022-02552-6∟. PMID: 36517865∟. Interventional study. ˍ

Krigers A, Klingenschmid J, Cosar T, Moser P, Thomé C, Freyschlag CF.
Age-Dependent Impact of Concomitant Radio-Chemotherapy and MGMT Promotor Methylation on PFS and OS in Patients with IDH Wild-Type Glioblastoma: The Real-Life Data.
Cancers (Basel). 2022 Dec 14;14(24):6180∟. doi: 10.3390/cancers14246180∟. PMID: 36551664∟. Observational study. ˍ

Ahluwalia MS, Reardon DA, Abad AP, Curry WT, Wong ET, Figel SA, Mechtler LL, Peereboom DM, Hutson AD, Withers HG, Liu S, Belal AN, Qiu J, Mogensen KM, Dharma SS, Dhawan A, Birkemeier MT, Casucci DM, Ciesielski MJ, Fenstermaker RA.
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
J Clin Oncol. 2022 Dec 15:JCO2200996∟. doi: 10.1200/JCO.22.00996∟. PMID: 36521103∟. Interventional study. ˍ

Minniti G, Tini P, Giraffa M, Capone L, Raza G, Russo I, Cinelli E, Gentile P, Bozzao A, Paolini S, Esposito V.
Evaluation of different tumor delineation strategies in patients with glioblastoma receiving standard chemoradiation: impact of reduced treatment volumes on patterns of recurrence and radiation dose to healthy brain tissue.
Radiother Oncol. 2022 Dec 15, 2022:S0167-8140(22)04581-9∟. doi: 10.1016/j.radonc.2022.11.024∟. PMID: 36529439∟. Observational study˰ ˍ